Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Legal Officer

Chief Executive Officer

Chief Medical Officer

Chief Legal and HR Officer

Chief Financial Officer

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evoluti...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-16	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-04-16	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-04-01	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-03-27	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-03-27	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-03-18	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-03-18	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-27	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-02-27	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-16	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-16	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-02-08	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-08	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-02-08	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-02-05	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-02-05	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-23	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-05	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-04	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-04	Premium	sold	Premium	Premium	Premium	-
2023-12-18	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-12-15	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2023-05-09	Premium	bought	Premium	Premium	Premium	-
2023-05-02	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer

FDMT - 4D Molecular Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for FDMT